Vigilance Reporting Timelines in Ethiopia: Three-Tier Deadlines Under EFDA-GDL-090

1. Key takeaways

Ethiopia applies a three-tier deadline structure to medical device vigilance reporting. A serious public health threat must be reported immediately and no later than 2 calendar days; within that tier, the practical meaning of immediate is a preliminary notification through any available channel within 48 hours, followed by a complete written report within 15 days. A death or a serious deterioration in health status must be reported no later than 10 calendar days. All other events fall under a deadline of no later than 30 calendar days. The applicable tier is determined by the nature of the event, not by the device classification, and the clock starts on the day the licence holder or manufacturer becomes aware of the event. Three consequences follow for any manufacturer selling into Ethiopia. First, event triage must be completed before any product-based reasoning, because the deadline attaches to the event itself. Second, the awareness date is the operative trigger, so the speed of internal complaint routing directly determines compliance. Third, the three tiers apply equally to imported products, which means overseas manufacturers ultimately depend on how fast their Ethiopian channel escalates safety information to them. The three-tier table below is therefore the single most consequential page of the vigilance guideline for day-to-day operations, and every downstream process, from complaint intake to archive design, should be derived from it rather than from habit imported from other markets.

2. Legal basis

3. Expert insights

Insight 1: the three-tier split is driven by the urgency of the harm, not by the risk class of the device.

A low-risk device that causes a serious public health threat still falls into the 2 calendar days tier, while a serious incident involving a minor event on a high-risk device is still handled under 30 calendar days. The most common corporate error is to preset reporting deadlines according to product classification. The predictable result is that a sudden public health event involving a low-risk product misses its window entirely, because the internal timetable was never designed for it.

Insight 2: the 48 hours and the 2 calendar days are two different actions, not a restatement of the same deadline.

48 hours refers to the preliminary notification: making EFDA aware through any available channel, such as telephone or email. 2 calendar days refers to the deadline for the formal report, and 15 days is the supplementary deadline for the complete written report. Together they form a progressive structure of notify first, report fast, then complete. Performing only one of the three steps does not discharge the obligation, and companies that treat the first notification as the whole duty systematically fall short of the guideline. The three actions also need three different owners and three different record sets, which is why they should be mapped separately in the SOP rather than merged into a single reporting step.

Insight 3: the clock starts on awareness, which is the least favourable arrangement for overseas manufacturers.

Vigilance obligations rest simultaneously on the manufacturer and the local representative (item 9.2.3(f) of EFDA-GDL-046 requires both parties to jointly assume vigilance and post-market reporting responsibilities). Where the local representative receives a hospital complaint and the manufacturer learns of it a week later, the deadline may still be treated as already running, because the representative is a party in the licence chain. This makes it essential to compress the internal workflow from user complaint to vigilance triage to the shortest possible duration, with no idle handoffs.

Insight 4: vigilance reporting is directly linked to re-registration.

Item 12.1(h) of EFDA-GDL-046 requires sterile devices, devices with a measuring function, and all Class III/C and above devices to submit vigilance and post-market surveillance reports at re-registration. Item 9.2.3(e) additionally requires evidence of safety and performance for the same product category within one year of placing on the market. Vigilance data is therefore both a compliance duty in its own right and mandatory supporting material for the year-5 re-registration exercise.

Insight 5: the reporting channels are already defined.

EFDA maintains a dedicated mailbox for device safety reports and accepts submissions through an online channel (practical estimate: the specific mailbox and online form should be taken as the ones currently published by EFDA; the current official announcements must be checked at the time of writing and of any submission).

4. Practical recommendations

1. Build a written three-tier triage tree: document the criteria for deciding whether an event constitutes a serious public health threat, together with the responsible persons, inside the SOP, so that no judgement is improvised during a live event.
2. Turn the 48 hours into a hard indicator: for any suspected serious public health threat, notify first and characterise later; do not spend the clock on internal debate about the tier.
3. Keep dual-channel records: the time, channel, recipient and content of every notification must be documented, as evidence that the deadline was met.
4. Synchronise awareness between the local representative and the manufacturer: agree contractually that complaints are forwarded within 24 hours, and share a single event numbering scheme.
5. Archive by re-registration scope: file vigilance records under the sterile, measuring, and Class III and above categories, ready for the year-5 re-registration and the one-year evidence submission.

5. Verification checklist

• □ Three-tier deadline criteria established (2 / 10 / 30 calendar days)
• □ Owner and channel defined for the 48-hour preliminary notification
• □ Responsible person named for submitting the complete written report within 15 days
• □ Awareness synchronisation mechanism agreed between the local representative and the manufacturer
• □ Time and recipient of every notification recorded
• □ Vigilance records archived against the re-registration and one-year evidence scopes
• □ Current EFDA reporting channels verified

Regulatory information verified as of 29 October 2026. The three-tier deadlines listed in this article follow the current text of the Medical Device Vigilance Guideline EFDA-GDL-090; when the guideline is revised or the authority publishes new reporting channels, the verification must be repeated.

• Local resource in Ethiopia: GRZAN assists manufacturers from the Chinese mainland and overseas in engaging the Ethiopian Food and Drug Authority (EFDA) on marketing authorisation (MA), Certificate of Competency (CoC) and import licence applications, including local representative structuring and agreement review, SRA reliance rationales, UMDN coding and classification, technical documentation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorisation applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles compliance arguments, labelling and instructions-for-use localisation (English), and vigilance reporting with field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.